# OrbiMed

> OrbiMed is a global healthcare investment firm spanning venture capital, growth equity, public equities and royalty/credit strategies. On October 15, 2026 it announced approximately $3B of commitments across Private Investments X (over $1.9B, US/European life-sciences VC) and Asia Partners VI (over $1B, Asian healthcare venture/growth). These are two distinct vehicles, not a single fund or startup round.

## Profile

- **Stage-based planning range:** $100K–$1M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** New York, United States
- **AUM:** Over $21B firmwide, as disclosed October 15, 2026; includes strategies beyond these two funds.
- **Rounds they lead:** N/A
- **Rounds they invest:** N/A
- **Last verified:** 2026-10-15T22:08:45Z

## Links

- [Website](https://www.orbimed.com/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/orbimed